Clinomics Inc. Overview
Celestra Inc., known until 2025 as Clinomics, was founded in 2011 as a liquid-biopsy and cancer-genomics company. In 2018 it merged with Zeromics, the genome-analysis company of UNIST professor Park Jong-hwa. It was the first UNIST faculty start-up to list on KOSDAQ, through the growth-potential special-listing track in December 2020. Its stated platform combined multi-omics genome analysis, an in-house device for isolating circulating tumour cells and cell-free DNA, and consumer and clinical genetic tests. COVID-19 testing, mainly through its US subsidiary, drove a one-off peak in FY2021 of KRW 55.4bn revenue and KRW 22.9bn operating profit. After demand collapsed, the company recorded large losses. Control passed to a new investor group in 2024, and the company moved into a hotel, a mushroom smart farm and health supplements. By 2025–2026 it had received two audit disclaimers, entered and then exited court rehabilitation, and was facing delisting. Its core diagnostics business has effectively stopped operating.
Company's own characterisation
The company's latest annual report (FY2025 business report) could not be retrieved directly. The most recent company-sourced business descriptions, as summarised by data vendors, are:
Core description (GuruFocus / Morningstar profiles): a biotechnology company offering genome-based early diagnosis of cancer and other diseases, which aims to address ageing and disease through liquid biopsy and multi-omics technology.
Business lines (EMIS profile, based on 2023 data): two main businesses.
-
A multi-omics service business that predicts physical traits and disease risk from genome tests and offers multi-omics-based early detection of major diseases such as cancer.
-
A liquid-biopsy cancer diagnosis and screening business that sells devices for isolating blood cells and DNA, along with diagnostic and monitoring kits for cancer mutations. It is also developing blood-based early cancer detection products.
Main products listed in IR disclosures (IRGO): Geno Series, CD-PRIME, Cancer Prime.
2025-era description (TheVC): NGS-based contract research services under B2B and B2C models, with revenue diversification through health functional foods and a hotel business.
Independent characterisation
From IPO to 2023, Clinomics was a small Korean clinical-genomics and liquid-biopsy services company. Its business model mixed three things:
-
Fee-for-service testing: consumer DTC genetic tests, clinical cancer panels and research sequencing.
-
Device and kit sales: liquid-biopsy sample-preparation devices and cancer-mutation kits.
-
Pandemic testing: COVID-19 diagnostic kits and lab testing, mainly through Clinomics USA in 2020–2022.
The COVID business masked the fact that the core genomics products never reached commercial scale (Bizwatch, Nov 2025). After the change of control in 2024, the company became a loosely connected holding of unrelated assets: a Seoul hotel, a 40% stake in a mushroom smart farm (Gageum Nongsan), and a health-supplement subsidiary (CoNF). The financial press reported that these acquisitions were made partly to stay above the KOSDAQ revenue threshold that triggers "administrative issue" designation (Financial News, Jul 2025; The Tracker, Sep 2025).
By 2026, operating activity was minimal. Standalone Q1 2026 revenue was about KRW 24 million. In the H1 2026 report, the company confirmed that Q2 revenue was below KRW 300 million and H1 revenue below KRW 700 million, and that its equity was fully impaired.
Revenue model mix
| Revenue type | Description | Approx. weight |
|---|---|---|
| Testing services (product-like service fees) | Genome, DTC and cancer tests; COVID-19 testing (historic) | Dominant in FY2020–FY2022. Exact split not publicly disclosed. |
| Product sales | Liquid-biopsy devices, diagnostic kits, COVID kits, health functional foods | — |
| Research services | NGS-based contract research | — |
| Hospitality | New Oriental Hotel (acquired 2024) | Not publicly disclosed. The hotel was reported as not operating at acquisition. |
| Subscription / licensing | Genpic app (an affiliate's app, not consolidated revenue); distribution of Singlera tests | — |
Value-chain position, customers and end-markets
Value chain: a mid-stream analysis-service provider. It sourced sequencing platforms from third parties and licensed some tests (Singlera's), while running its own lab analysis, bioinformatics and reporting. Its in-house sample-preparation device for CTC and ctDNA isolation was the main upstream differentiator.
Customers: hospitals and clinics (cancer panels), consumers (DTC tests under Korea's limited DTC regime), research institutions (sequencing services), government (it carried out national R&D projects, including 2023 work on infectious diseases and epidemiological and mathematical modelling, per TheVC), and in 2020–2022 COVID-testing clients in the US.
End-markets: precision oncology and liquid biopsy, consumer genomics and wellness, infectious-disease diagnostics, and from 2024 hospitality and agri-food.
Strategy
Stated strategic themes (company statements, paraphrased)
At IPO (2019–2021): become a bio-big-data-based disease prediction and diagnosis company. Pursue multi-omics early cancer detection through multi-centre trials in colorectal, lung and gastric cancer. Build genome big-data infrastructure in Ulsan, Gwanggyo and Osong. Recruit global talent from the UK and US.
2022 mission framing (IR deck): a three-step path from genome company to disease-diagnosis company to disease-treatment company, under the goal of people living longer without illness.
2022 healthcare roadmap: offer personalised health information from genetic, health and life-log data, and prescribe exercise, diet, teas and supplements. Expand into wellness and beauty devices (CEO Jung Jong-tae, Oct 2022).
2023 early cancer detection: take an early lead in the cancer-screening market, which the company sized at tens of trillions of won, through exclusive supply of Singlera's tests in the US, Europe and Korea (CEO Kim Byung-chul, May 2023).
- 2024 "Genocare" project (Clinic, Application, Report, Engine): use the Geno Engine for large-scale genome data and AI to generate reports, personalised supplements (via Gageum Nongsan and CoNF) and clinic services. Build a big-data platform combining EMR and personal health data with partners in universities, hospitals, pharma, insurance and food. Develop ADC, glyco-engineered drugs and anti-ageing ("reverse aging") products. A planning and marketing new-business division was created.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Outcome |
|---|---|---|---|
| Fifth-series CB financing | Mar 2025 | Working capital for existing and new businesses | Redeemed early, Apr 2025 |
| 15:1 capital reduction | Apr 2025 | Offset accumulated deficit | Completed 17 Apr 2025 |
| Re-audit plan | Jul 2025 | IB sources said a re-audit was planned to obtain a clean opinion and resume trading | Not achieved; FY2025 also disclaimed |
| Stalking-horse sale of the company | Jul 2025 | Samil PwC appointed sale adviser | No buyer disclosed |
| Court rehabilitation | Sep 2025 – Aug 2026 | Filed 8 Sep 2025; commenced 30 Sep 2025; about 10 public notices through Jun 2026 | Terminated 20 Aug 2026; no plan filed |
| Hotel resale | 2,025 | Divestment of New Oriental Hotel | Outcome not disclosed |
| Investor search / re-filing for rehabilitation | Aug 2026 | Company said it would consider re-filing once a new investor is secured | Pending |
| Injunction against delisting | Jun 2026 – | Court challenge to the KRX decision | Pending at cut-off |
Medium-term targets and guidance
| Target | Set | Actual |
|---|---|---|
| Revenue of at least KRW 20bn in 2024 | Jul 2024 (Genocare) | KRW 8.5bn (FY2024) |
| Revenue of at least KRW 50bn and profitability from 2025 | Jul 2024 (Genocare) | KRW 2.0bn revenue, KRW 7.8bn operating loss (FY2025) |
| Equity ratio from 44.89% to 67.59% via 2023 rights offering | May 2023 | Rights offering downsized; ratio outcome not disclosed |
No current guidance has been published. ESG and sustainability commitments are not publicly disclosed.
Products & Services
The list below covers every product that could be identified. Specifications and pricing are mostly not publicly disclosed.
Genome / multi-omics services
| Product | Description | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| Geno Series (incl. Geno-P) | DTC genetic tests within Korea's permitted DTC test items. Geno-P was one of about 10 genome tests offered at IPO. | Consumers | Pre-2021 | — |
| Genome-based personalised healthcare tests | Trait and disease-risk prediction from genome analysis | Consumers, clinics | Pre-2021 | — |
| Multi-omics early disease detection | Early detection of major diseases including cancer | Hospitals, health-screening centres | Under development; commercialisation targeted for 2023 | — |
| Stress/depression early diagnosis service | Development project targeting commercialisation in 2023 | Clinics | Status not disclosed | — |
| NGS research services | Sequencing-based contract research | Universities, institutes, government | Ongoing (TheVC) | — |
| Geno Engine / Geno Report | Large-scale genome data production and AI/multi-omics reporting (Genocare framework) | B2B partners, clinics | Announced Jul 2024 | — |
Liquid biopsy and cancer diagnostics
| Product | Description | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| CTC/ctDNA isolation platform | Platform that separates circulating tumour cells and cell-free tumour DNA from blood. Founder Kim cited owning both capabilities as the company's key differentiator. | Oncology labs, hospitals | Pre-IPO | — |
| CD-PRIME | Listed as a main product (IRGO). Detailed specifications not publicly disclosed. | Oncology | — | — |
| Cancer Prime | Listed as a main product (IRGO); cancer companion-diagnostic / panel offering | Oncology | — | — |
| Cancer mutation diagnostic and monitoring kits | Kits for patient cancer-mutation detection and monitoring | Hospitals | Pre-2023 | — |
| Liquid-biopsy early cancer detection platform | Blood-based early detection; multi-site trials planned for colorectal, lung and gastric cancer | Screening market | Development; commercialisation targeted for 2023 | — |
| ColonES (Singlera) | Colorectal cancer early detection | US market via Clinomics USA | Launch planned H2 2023 | — |
| PDACatch (Singlera) | Pancreatic cancer early detection | US market | Launch planned H2 2023 | — |
| Panseer MRD (Singlera) | Multi-cancer / minimal residual disease testing | US market | Launch planned H2 2023 | — |
| ColonAiQ (Singlera) | Colorectal cancer screening | Europe via Clinomics EU | Launch planned 2023 | — |
| HepaAiQ (Singlera) | Liver cancer screening | Europe via Clinomics EU | Launch planned 2023 | — |
Actual commercial revenue from the Singlera-licensed tests was not publicly disclosed. Consolidated revenue fell after 2023, which suggests sales were immaterial.
Infectious disease (historic)
| Product | Description | Status |
|---|---|---|
| COVID-19 diagnostic kits and testing services | Testing infrastructure in Korea, the US and Europe; US lab testing drove FY2021 revenue | Ended after the pandemic |
Therapeutics R&D
| Program | Description | Status |
|---|---|---|
| AI personalised cancer vaccine (Zeromics) | Neoepitope prediction via AI "bio genome engine"; humanised-mouse preclinical work with Humic | MOU Aug 2023; no later progress disclosed |
| Glyco-engineering drugs, ADC technologies | Listed as partnership targets under Genocare | Concept stage (Jul 2024) |
Wellness, health foods and non-core
| Product / asset | Description | Status |
|---|---|---|
| "Epi's Today" (에피의오늘) | Supplement brand of subsidiary Episday (diet tea, nutritional supplements) | Launched 2022 |
| CoNF health functional foods | Personalised and anti-ageing supplements | Acquired 2023 |
| Genpic app (affiliate The Contest) | Post-test personalised health content by subscription | Launched 1 Oct 2022 |
| New Oriental Hotel | Seoul hotel; reported as not operating at acquisition | Being resold (Nov 2025) |
| Gageum Nongsan mushroom smart farm (40%) | Automated mushroom cultivation | Held (status not disclosed) |
Financial Narrative
Source: Butler.works company page (OpenDART-based consolidated annual data, FY2021–FY2025). FY2021–FY2022 figures are cross-checked with Bizwatch (Nov 2025) and FY2022/FY2024 with The Tracker (Sep 2025). FY2024 and FY2025 statements carry disclaimers of opinion. Blank cells mean not publicly disclosed in accessible sources.
Income statement
FY2020 reference: revenue KRW 9.8bn, operating loss KRW 12.3bn (Daishin IPO report). The FY2021 growth rate is calculated against this base. The company has never paid a dividend (GuruFocus).
Margins (%)
Margins are calculated from the rounded figures in 6.1.
Revenue CAGR: FY2021–FY2025 about -56.4% a year (KRW 55.4bn to KRW 2.0bn). FY2020–FY2025 about -27.2% a year.
Cash flow
Line-item cash flows are not publicly disclosed in accessible sources. Bizwatch (Nov 2025) reports that the company burned several billion to tens of billions of won each year across operating and investing activities, funded by CBs, rights offerings and borrowings. It also reports that the KRW 30bn CB raised in 2021 had to be repaid with proceeds from the 2023 shareholder rights offering.
Financing events (chronological):
TheVC records a total of six CB issues over the company's history.
Ratios
Current ratio source: TheVC (financial detail summary, FY2023–FY2025).
Commentary on trends, inflections and drivers
FY2021 (peak): Revenue of KRW 55.4bn and operating profit of KRW 22.9bn came from pandemic COVID testing, which exploded through the US subsidiary (Bizwatch). The 41% operating margin reflects pandemic testing economics, not the core genomics business. This was the single point at which the company had resources. It used them to buy a building in Irvine and a lab in San Diego and to raise KRW 30bn in CBs, rather than to build lasting revenue in its core business.
FY2022 (first inflection): As COVID testing faded, revenue fell 58% to KRW 23.1bn and the company swung to an operating loss of KRW 10.8bn. R&D, clinical, equipment and personnel costs stayed fixed while no new cash generator emerged (Bizwatch). The company also committed KRW 8.2bn to Nuribio.
FY2023 (collapse in profitability): Revenue halved again to KRW 11.4bn and the operating loss tripled to KRW 34.6bn. The net loss of KRW 42.4bn likely includes impairments and valuation losses, though the components were not disclosed. Pre-tax loss reached 108.8% of equity, more than twice the 50% KOSDAQ threshold. The special-listing exemption from that test lasts three years, so it expired around this time (Dealsite, Jul 2024). The auditor flagged going-concern uncertainty.
FY2024 (pivot to non-core assets): Under new control, the company bought a hotel (KRW 18.5bn) and a farm stake to support revenue. Revenue still fell to KRW 8.5bn against a KRW 20bn target, and the net loss widened to KRW 47.1bn. The audit ended in a disclaimer.
FY2025 (wind-down): Revenue of KRW 2.0bn was down about 76%. The operating loss narrowed to KRW 7.8bn, which reflects a smaller cost base (employees fell toward single digits by mid-2026), not recovery. The current ratio fell to 27.3%, meaning current assets covered about a quarter of current liabilities. A second disclaimer followed.
H1 2026: Q1 standalone revenue was about KRW 24 million. Revenue thresholds under the KOSDAQ "suspended main business" test were breached in Q1, Q2 and H1, and equity was fully impaired at 30 June 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (as described) | Contents | Status at cut-off |
|---|---|---|
Multi-omics / genome-based healthcare services | DTC and clinical genetic tests (Geno Series, Geno-P), multi-omics early detection, NGS research services, big-data analysis | Effectively dormant. H1 2026 revenue below KRW 0.7bn. |
Liquid-biopsy cancer diagnosis and screening | CTC/ctDNA isolation devices, cancer mutation diagnostic and monitoring kits (CD-PRIME, Cancer Prime), Singlera-licensed screening tests | Not publicly disclosed; no evidence of current sales |
COVID-19 diagnostics (historic) | Kits and lab testing, mainly via Clinomics USA | Ended after the pandemic |
Health functional foods | CoNF subsidiary, Episday ("Epi's Today" brand), personalised supplements under Genocare | — |
Hospitality | New Oriental Hotel, Seoul | Being resold (Bizwatch, Nov 2025); outcome not disclosed |
Agri-food (equity-accounted) | 40% of Gageum Nongsan (mushroom smart farm) | — |
“—” = not publicly disclosed.
Revenue by Segment
| Segment (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total consolidated revenue (KRW Bn) | 11.4 | 8.5 | 2.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Relationship | Business | Source |
|---|---|---|---|
Clinomics USA Inc. | Subsidiary | US operations: COVID testing (2020–22), distribution of Singlera's ColonES, PDACatch and Panseer MRD; Irvine, CA building | IR 2021; Medigate (May 2023); Bizwatch (Nov 2025) |
Clinomics EU | Subsidiary/branch | European launch of ColonAiQ and HepaAiQ screening (planned 2023) | Medigate (May 2023) |
Zeromics (제로믹스) | Subsidiary (2023 reference) | AI-based anti-cancer and anti-ageing drug development; cancer-vaccine system | Medigate (Aug 2023) |
Episday (에피스데이) | Subsidiary (est. early 2022) | Health functional foods ("Epi's Today") | Medigate (Oct 2022) |
CoNF (코엔에프) | Subsidiary (acquired 2023) | Health functional foods | Medigate (May 2023); Asiae (Jul 2024) |
Gageum Nongsan (가금농산) | 40% equity stake (2024) | Mushroom smart farm / automated cultivation | Financial News (Jul 2025) |
Nuribio (누리바이오) | 28.40% equity stake (Nov 2022) | Cancer early-diagnosis related | Dealsite (Nov 2022) |
The Contest (더콘테스트) | Affiliate | Genpic gene-based health app | Medigate (Oct 2022) |
New Oriental Hotel | Owned asset (acquired May 2024) | Hotel, Jung-gu, Seoul | Financial News (Jul 2025) |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 55.4 | 23.1 | 11.4 | 8.5 | 2.0 |
Revenue growth YoY (%) | 465.3 | -58.3 | -50.6 | -25.4 | -76.5 |
Operating income (KRW Bn) | 22.9 | -10.8 | -34.6 | -28.7 | -7.8 |
Net income (KRW Bn) | 15.9 | -10.2 | -42.4 | -47.1 | -11.8 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating margin (%) | 41.3 | -46.8 | -303.5 | -337.6 | -390.0 |
Net margin (%) | 28.7 | -44.2 | -371.9 | -554.1 | -590.0 |
Key Financials and Margin Analysis (%)
| Metric | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Accumulated deficit (KRW Bn) | 26.3 | — | — | — |
Current ratio (%) | — | 135.4 | 37.7 | 27.3 |
Datapoint Details
| Datapoint | Value | Date | Source |
|---|---|---|---|
Accumulated deficit | KRW 60.5bn | Q3 2024 | Dealsite (Mar 2025) |
Pre-tax loss / equity | 108.8% | FY2023 | Dealsite (Jul 2024) |
Real-estate value (Ulju plant site, Osong lab) | about KRW 9.5bn (due-diligence value) | Jul 2025 | Financial News (Jul 2025) |
Cash | about KRW 0.63bn | Q3 2025 | Craft.co (aggregator) |
Equity status | Fully impaired (자본전액잠식) | 30 Jun 2026 | KRX notice via Topstar News (Aug 2026) |
Debt / equity (aggregator snapshot) | 0.43 | Date not stated | GuruFocus |
Cash / debt (aggregator snapshot) | 0.54 | Date not stated | GuruFocus |
Altman Z-score (aggregator) | -1.8 | Date not stated | GuruFocus |
Piotroski F-score (aggregator) | 3/9 | Date not stated | GuruFocus |
IPO offer price | 13,900 | Dec 2020 | NewsTomato |
Price | 15,200 | 29 Jun 2021 | Daishin |
Price | 593 | 29 Oct 2024 (market cap KRW 22.8bn) | Craft.co |
Last traded price (post-reduction basis) | 5,250 | Halted since Apr 2025 | Simply Wall St; Investing.com |
52-week high / low (as displayed) | 25,410 / 4,245 | Aggregator display; reference period unclear | Simply Wall St |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Instrument by Date
| Date | Instrument | Size | Use / note | Source |
|---|---|---|---|---|
Apr 2019 | Pre-IPO equity | KRW 22.5bn | Cancer early-detection R&D, clinical trials | DailyPharm |
Dec 2020 | IPO | — | Growth-potential listing | NewsTomato |
| 2021 | Convertible bonds | KRW 30bn | Growth investment; later repaid via 2023 rights offering | Bizwatch |
May–Aug 2023 | Rights offering + 0.5 bonus issue | Announced KRW 44.6bn; final amount reduced after the price fell about 40% | CB repayment; equity ratio targeted to rise from 44.89% to 67.59% | Medigate; NewsTomato |
Apr 2024 | Third-party allotment to Geno Investment Association No. 1 | KRW 7.6bn | Change of control (12.99%) | Daum/news |
| 2024 | CBs (incl. third series KRW 12bn secured on hotel) | KRW 25bn total CBs in that round | Hotel purchase, loan repayment. Of KRW 32.6bn raised, about KRW 6.8bn cash remained. | Daum/news (2024) |
18 Mar 2025 | Fifth-series CB | About KRW 5–5.5bn | Working capital; redeemed early on 7 Apr 2025 | Dealsite; Chosun Biz |
17 Apr 2025 | Capital reduction 15:1 (93.33%) | — | Offset accumulated deficit | IRGO; Bloter |
Margin Analysis (%) (FY2023–FY2025)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Current ratio (%) | 135.4 | 37.7 | 27.3 |
Revenue by Region
| Region (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 11.4 | 8.5 | 2.0 |
Capital Markets
| Metric | 1-year | 3-year | Since IPO |
|---|---|---|---|
Share price change (%) | -76.5 | -92.8 | -97.2 |
Valuation Multiples
| Multiple | Celestra | Macrogen | Note |
|---|---|---|---|
Market cap (KRW Bn) | 13.6 | 132.0 | Butler.works (Macrogen at the time of the aggregator snapshot) |
P/E (x) | n/m (losses) | 12.83 | Butler.works |
P/B (x) | n/m (equity fully impaired) | 0.85 | Butler.works |
P/S (x) | About 6.8 on FY2025 revenue (13.6 / 2.0). Simply Wall St earlier cited 3.5x at an unspecified 2025 date. | — | Calculated; Simply Wall St |
Capital Markets — Analyst consensus / target price
| Item | Status |
|---|---|
Analyst consensus / target price | None. No analyst estimates are available (Simply Wall St). The only broker report found is Daishin's mandatory IPO-manager coverage (2021, not rated). |
Dividend history / policy | No dividends paid since listing (GuruFocus) |
Buyback authorisations | None disclosed; treasury shares 1.50% (Butler.works) |
Credit ratings (Moody's / S&P / Fitch) | None (unrated) |
Debt maturity profile | Not publicly disclosed. CBs carried a 3% coupon and 9% yield-to-maturity in at least one 2024 issue (Daum/news). Repayment terms are now subject to insolvency outcomes. |
Valuation Snapshot
| Metric | Value |
|---|---|
Shares outstanding pre-reduction (Q1 2024) | 38,143,171 |
Capital reduction ratio (Apr 2025) | 15 to 1 (93.33%) |
Shares outstanding (Jun 2026) | 2,592,407 |
Analyst Conclusions
Management guidance and consensus
The company has published no current guidance. The last quantitative targets (July 2024 Genocare: at least KRW 20bn revenue in 2024 and at least KRW 50bn with profitability from 2025) were missed by wide margins. No sell-side consensus exists. Management's only stated forward intention is to find a new investor and then consider re-filing for rehabilitation (Bloter, Aug 2026).
Bull case
-
Court relief preserves the listing. If the Seoul Southern District Court grants the injunction (2026카합1390), the delisting decision is suspended, and a listed shell with hard assets could attract a reverse-merger or recapitalisation investor. IB sources said this in July 2025.
-
Hard-asset backstop. Real estate valued at about KRW 9.5bn (July 2025) plus a hotel bought for KRW 18.5bn is large relative to the stale market cap of about KRW 13.6bn. That gives creditors and any acquirer collateral to work with.
-
Sector precedent for rescue. EDGC followed the same path (disclaimer, rehabilitation) and was acquired by Erom Holdings for KRW 31.5bn. Distressed Korean genomics assets can find strategic buyers.
Bear case
-
Multiple independent delisting triggers. Even if the audit-based decision is suspended, other causes remain: quarterly revenue below KRW 300m, H1 revenue below KRW 700m, full capital impairment and rehabilitation termination. Each can sustain delisting on its own.
-
No going concern. Two audit disclaimers, a 27.3% current ratio, roughly 9 employees, and termination of rehabilitation because no plan could be funded leave equity holders likely to recover nothing in bankruptcy.
-
Governance and legal overhang. Criminal complaints against the CEO and the questions about related-party CB redemption reduce the chance that any reputable investor commits capital before the investigations conclude.
Key catalysts and monitorables (next 12 months)
-
Ruling on injunction 2026카합1390 (Seoul Southern District Court), and any appeal.
-
Disposition of the November 2025 bankruptcy petition.
-
Any new rehabilitation filing backed by a named investor.
-
Outcome of the hotel resale and of any creditor enforcement against pledged assets.
-
Progress of the complaints lodged with the Suwon District Prosecutors' Office and the FSS.
-
Q3 2026 quarterly report (due mid-November 2026) and its review opinion.
-
KRX action on the substantive-review causes once the injunction is resolved.
-
Details of the 23 September 2026 head-office relocation, as a signal of the remaining operating footprint.
Analyst verdict
Celestra Inc., formerly Clinomics, is no longer an operating genomics company in any meaningful sense. It is a distressed legal entity whose remaining value depends on court decisions, creditor recoveries and possibly a listing shell. The investment case once rested on credible scientific foundations: a UNIST genomics pedigree, a dual CTC/ctDNA isolation platform, 35 patents, and exclusive rights to Singlera's early-detection tests. That case was undone by poor capital allocation.
The FY2021 COVID windfall of KRW 55.4bn revenue and KRW 22.9bn operating profit was not converted into recurring diagnostics revenue. US real estate, equity stakes and CB-funded expansion consumed the cash. After the 2024 change of control, the company bought a dormant Seoul hotel and a mushroom-farm stake to support reported revenue. Revenue still fell to KRW 2.0bn in FY2025, and quarterly standalone revenue reached about KRW 24 million in Q1 2026.
The financial record since FY2024 is effectively unverifiable because of two audit disclaimers. Equity was fully impaired at mid-2026. Rehabilitation failed in August 2026 because no investor could be found. KRX has decided to delist, and only a pending injunction prevents that from taking effect. Even a favourable ruling would leave several other delisting triggers in place, including revenue thresholds and full capital impairment. Criminal complaints against the current CEO add legal risk and further deter capital.
For institutional purposes, the equity should be treated as at high risk of total loss. Value, if any, lies with secured creditors, the real estate (about KRW 9.5bn in mid-2025 estimates) and the hotel, and possibly in a recapitalised shell if the courts and KRX allow it. The case is a clear example of the structural weaknesses Korean commentators have identified in special-listing genomics companies: technology without a proven business model, pandemic revenue mistaken for durable growth, and weak governance during a change of control.
Rating stance (independent): Not rated / avoid. Risk of total loss for equity holders is critical.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / notes |
|---|---|---|---|
Baek Seo-hyeon (백서현) | CEO (sole CEO after founders left) | Joined management 2023; co-CEO by Q1 2024; sole CEO thereafter | Runs Brand Refactoring, a private digital-marketing company founded in 2022, in which she holds 60%. The market viewed her takeover as effectively hostile (Asiae, Aug 2025). Subject of criminal complaints in Sep 2025 and Aug 2026. |
Lee Sang-yoon (이상윤) | Inside director, in charge of R&D | Through at least Mar 2025 | Born 1995. Owns 100% of Dominate, the subscriber of the fifth-series CB (Mar 2025). |
Jung Jong-tae (정종태) | Formerly CFO/COO (2019), co-CEO (2022–2023); "management head" in the Q1 2024 report | 2019 – at least May 2024 | Led IPO preparation (IFRS, LIMS, internal systems) |
Kim Byung-chul (김병철) | Founder; CEO / co-CEO | 2011 – 2024 | Ex-POSTECH, Theragen Etex bio-institute. Left in 2024. |
Park Jong-hwa (박종화) | Co-CEO (2019); largest shareholder at IPO | Until 2024 | UNIST professor; produced the first Korean human genome map. Sold shares in 2023 to fund his rights-offering participation. Left in 2024. |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
| 2023 | Baek Seo-hyeon joins management | Entry of the Geno Investment Association No. 1 group |
By Q1 2024 | Co-CEOs Kim Byung-chul and Baek Seo-hyeon | Transition period |
| 2024 | Founders Kim Byung-chul and Park Jong-hwa leave | After the change of control and non-core acquisitions (Bizwatch) |
2024–2025 | Baek Seo-hyeon becomes sole CEO | Founders and earlier CEOs were pushed out (Asiae) |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Geno Investment Association No. 1 (Seoul, Gangnam-gu) | 12.99% | Apr 2024 (pre-capital-reduction) | KIND ownership report; Daum/news |
Park Jong-hwa and 8 related parties | 23.90% | Mid-2021 (post-IPO) | Daishin IPO report |
Treasury shares | 1.50% | 2026 | Butler.works |
Dominate (Lee Sang-yoon) | Potential via fifth-series CB conversion rights; CB redeemed Apr 2025 | Mar–Apr 2025 | Dealsite; Chosun Biz |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Latest revenue (verified) | Positioning vs. Celestra |
|---|---|---|---|
Macrogen (KOSDAQ 038290) | NGS services, DTC genomics, clinical genomics | KRW 195.3bn FY2025, +43.8% YoY; operating profit KRW 0.2bn | Market leader with global scale; returned to profit |
Eone Diagnomics Genome Center (EDGC, KOSDAQ 245620) | Genome diagnostics, liquid biopsy, NIPT | KRW 30.6bn FY2024; KRW 6.2bn in 9M 2025 | Closest analogue: special listing, disclaimer (Apr 2024), rehabilitation (May 2024), sold to Erom Holdings for KRW 31.5bn (deal closing Feb 2026) |
Labgenomics (KOSDAQ 084650) | Molecular diagnostics, NGS, COVID testing, US CLIA labs | — | Bought US CLIA labs (QDx, IMD) for about KRW 93bn to replace COVID revenue |
Celemics (KOSDAQ) | NGS target-capture kits, sequencing services | KRW 6.7bn FY2024; operating loss KRW 1.9bn | Similar-sized special-listing NGS firm, still listed |
Theragen Bio | Genome analysis, DTC | — | Domestic genomics peer |
Genomictree | Methylation-based early cancer detection | — | Early-detection rival |
Gencurix | Cancer molecular diagnostics | — | Oncology diagnostics rival |
Ngenebio | NGS cancer panels | — | Clinical NGS rival |
DNA Link | Genome analysis services | — | Domestic genomics peer |
GC Genome (private) | Liquid biopsy, NIPT, cancer screening | — | Liquid-biopsy rival |
Guardant Health (Nasdaq) / Grail (Nasdaq) / Exact Sciences (Nasdaq) | Global liquid biopsy and multi-cancer early detection | — | Global leaders in Celestra's target category |
23andMe (formerly Nasdaq) | DTC genomics | n/a — filed Chapter 11 in Mar 2025 | Global evidence of DTC genomics business-model stress |
Peer Comparison FY2025
| Metric | Celestra (FY2025) | Macrogen (FY2025) | EDGC (FY2024) | Celemics (FY2024) |
|---|---|---|---|---|
Revenue (KRW Bn) | 2.0 | 195.3 | 30.6 | 6.7 |
Revenue growth YoY (%) | -76.5 | 43.8 | -65.4 | 1.5 |
Operating income (KRW Bn) | -7.8 | 0.2 | -12.6 | -1.9 |
Operating margin (%) | -390.0 | 0.1 | -41.2 | -28.4 |
Peer Comparison FY2025 (FY2021–FY2025)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Macrogen revenue (KRW Bn) | 129.2 | 138.6 | 132.8 | 135.8 | 195.3 |
Macrogen operating income (KRW Bn) | 11.8 | 5.3 | -0.4 | -6.5 | 0.2 |
Celestra revenue (KRW Bn) | 55.4 | 23.1 | 11.4 | 8.5 | 2.0 |
Celestra operating income (KRW Bn) | 22.9 | -10.8 | -34.6 | -28.7 | -7.8 |



